998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation

V. Subbiah; B. Bashir; A.B. El-Khoueiry; S. Punekar; M.R. Khawaja; M. Gutierrez; A.J. Olszanski; M. Bilusic; S.M. Arnold; A.J. Scott; J.D. Berlin; D. Oh; A. Schoenfeld; D.B. Zhen; C-Y.A. Liao; J. Shepherd; K. McEachern; L.C. Harshman; J.J. Luke; T.A. Yap

doi:10.1016/j.annonc.2025.08.1567

Back

998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation

Journal article

Peer reviewed

998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation

V. Subbiah, B. Bashir, A.B. El-Khoueiry, S. Punekar, M.R. Khawaja, M. Gutierrez, A.J. Olszanski, M. Bilusic, S.M. Arnold, A.J. Scott, …

Annals of oncology, Vol.36, pp.S652-S653

2025-09

DOI: https://doi.org/10.1016/j.annonc.2025.08.1567

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

Details

Title: 998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation
Creators: V. Subbiah - Sarah Cannon Research Institute
B. Bashir - Thomas Jefferson University
A.B. El-Khoueiry - USC Norris Comprehensive Cancer Center
S. Punekar - Medical Oncology, New York University Langone Health, Perlmutter Cancer Center, New York, NY, United States of America
M.R. Khawaja - Hematology Oncology, Honor Health Research and Innovation Institute, Scotsdale, AZ, United States of America
M. Gutierrez - Hackensack University Medical Center
A.J. Olszanski - Fox Chase Cancer Center
M. Bilusic - Genitourinary Medical Oncology, UH Health - University of Miami Health System - Miller School of Medicine, Coral Gables, FL, United States of America
S.M. Arnold - University of Kentucky
A.J. Scott - Medicine Department, University of Arizona Cancer Center, Tucson, AZ, United States of America
J.D. Berlin - Vanderbilt University Medical Center
D. Oh - University of California, San Francisco
A. Schoenfeld - Memorial Sloan Kettering Cancer Center
D.B. Zhen - University of Washington
C-Y.A. Liao - University of Chicago
J. Shepherd - Clinical Development, Clasp Therapeutics, Cambridge, MA, United States of America
K. McEachern - Translational Medicine, Clasp Therapeutics, Cambridge, MA, United States of America
L.C. Harshman - Clinical Development, Clasp Therapeutics, Cambridge, MA, United States of America
J.J. Luke - University of Pittsburgh
T.A. Yap - The University of Texas MD Anderson Cancer Center
Publication Details: Annals of oncology, Vol.36, pp.S652-S653
Publisher: Elsevier Ltd; AMSTERDAM
Number of pages: 2
Grant note: Clasp Therapeutics
Funding: Clasp Therapeutics.
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032900560902976